Dermapharm Holding SE
Dermapharm Holding SE (DMPHF) Revenue
Annual & quarterly revenue history · segment & region breakdown
DMPHF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsDermapharm Holding SE trailing twelve-month (TTM) revenue is $1.17B, a decrease of 1.37% year-over-year from $1.16B in FY2025.
Revenue trend
2025 – 2014 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $1.16B | -$0.02B | -1.37% |
| 2024-12-31 | $1.18B | +$0.03B | +2.61% |
| 2023-12-31 | $1.15B | +$0.13B | +12.29% |
| 2022-12-31 | $1.02B | +$0.08B | +8.68% |
| 2021-12-31 | $0.94B | +$0.15B | +18.78% |
| 2020-12-31 | $0.79B | +$0.09B | +13.26% |
| 2019-12-31 | $0.70B | +$0.13B | +22.44% |
| 2018-12-31 | $0.57B | +$0.11B | +22.54% |
| 2017-12-31 | $0.47B | +$0.02B | +5.09% |
| 2016-12-31 | $0.44B | +$0.06B | +15.50% |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare DMPHF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Dermapharm Holding SE receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Dermapharm Holding SE reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in EUR.
Data sourced from Dermapharm Holding SE's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
DMPHF revenue · 4 questionsDMPHF's trailing twelve-month (TTM) revenue is $1.17B. That is a decrease of 1.37% year-over-year from $1.16B in FY2025.
▸ Source: FMP · Dermapharm Holding SE SEC filings · GAAP · Dermapharm Holding SE SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026